Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
RJ Rodenburg, FALM EskensErasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, The NetherlandsAbstract: Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the t...
| Autores principales: | , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2019-05-01
|
| Colección: | International Journal of Nephrology and Renovascular Disease |
| Materias: | |
| Acceso en línea: | https://www.dovepress.com/tivozanib-for-the-treatment-of-renal-cell-carcinoma-patient-selection--peer-reviewed-article-IJNRD |